Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
about
Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexesClobazam monotherapy for partial-onset or generalized-onset seizuresClobazam monotherapy for partial onset or generalized onset seizuresClobazam as an add-on in the management of refractory epilepsyUpdate on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.Interactions of clobazam with conventional antiepileptics in children.On the use of tranquillisers in epilepsy.Clobazam.Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome.Clobazam for patients with Lennox-Gastaut syndrome and epilepsy.Clobazam: a newly approved but well-established drug for the treatment of intractable epilepsy syndromes.Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy.Testing antiepileptic drugs in children.Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy.Role of clobazam in the treatment of epilepsies.Clobazam for intractable pediatric epilepsy.Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.The Role of Benzodiazepines in the Treatment of Epilepsy.Dehydration in dying patients.Clobazam as Add-on Therapy for Temporal Lobe Epilepsy and Hippocampal SclerosisEffect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy
P2860
Q21090654-533C9FF7-5A44-49B8-8005-EE7BC29E4132Q24193187-C44BB9CB-5091-4DB0-9350-63056E19B1C8Q24235129-B65574C4-E75A-482D-8EC4-D0EEEA45F745Q24243094-D743221A-32FC-4CAD-A953-E9B873841339Q33664128-0F7B0527-23D0-4D2E-9A42-1034B0264119Q34424215-7B8D0F40-8F08-4D94-BDE6-D3A11EA26574Q34570599-887E91DF-ACCC-492D-8467-987C89A28CC4Q36697498-F650A5EA-2B0C-4D77-A968-905DB2729713Q37715506-FC1BAA8F-43E9-4B5A-8F20-4B644B27D6A3Q37997090-9DD6AA8C-1E64-44D5-A0A4-EF54B540C020Q38056697-AEB1B912-5E21-40F4-93ED-6E9B1B960651Q38444948-DB96EEB9-98E5-4547-8F38-90248CF4821EQ40570299-A4126530-0D18-4C8D-9317-DC188D3DBBF5Q42653866-A548A74F-2CBC-4697-9DA2-DCB55988F7C2Q43265620-4A6A7451-839A-4C64-B00A-89E0D1379DBEQ45082371-649B95CC-1FB9-4FC7-934A-93B08C28062CQ46605318-DE1C8590-144E-4A8B-B95F-73DCD4D36812Q48062640-1ED43622-73D2-450F-A36F-1D75486297FCQ48794679-D16AF1FF-02FC-4CE3-8841-37B9384AD047Q57086568-F3547BB0-B735-499A-AA71-E06D94A505D7Q57770173-673D80B5-34AB-4733-BD20-A34E60EBB0B3
P2860
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
description
article
@en
im Juni 1991 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 1991
@uk
name
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
@en
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
@nl
type
label
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
@en
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
@nl
prefLabel
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
@en
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
@nl
P1433
P1476
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti
@en
P2860
P304
P356
10.1111/J.1528-1157.1991.TB04670.X
P577
1991-06-01T00:00:00Z